Sahajanand Medical Technologies Limited – Investor Presentation Summary

Key Operational Highlights

  • Commercial presence in multiple global countries with manufacturing facilities in India (Sachin SEZ, Surat and Telangana) and Thailand (Nonthaburi)
  • Capacity utilization: DES 79% at Surat plant, 20% at Telangana plant; Catheter 72% at Surat, 57% at Telangana; TAVI 53% at Thailand plant; Occluder 46% at Thailand plant
  • Telangana plant uses only 33% of its total area, leaving significant room for capacity expansion
  • Key drivers: New product launches (Sironity DCB), geographic expansion, operational efficiency improvements

Segment-wise Performance

Revenue by Product Category (H1 FY27): Not specified in exact figures but growth across all three categories

Revenue by Region (H1 FY27):

  • India: 24% share, +15% growth in Q2 after +6% in Q1
  • Europe: 36% share, +23% growth consistently in both quarters
  • Rest of World: 40% share (largest region), +37% growth in H1 (+43% in Q1, +32% in Q2)

Explanation of significant changes: RoW became the largest revenue region due to fastest growth rates, while Europe maintained steady growth and India showed improved growth in Q2.

Financial Highlights

Q2 FY27 Performance:

  • Revenue: ₹3,734 mn (+24.7% YoY)
  • EBITDA: ₹656 mn (+36.6% YoY)
  • PAT: ₹265 mn (+26.6% YoY)
  • EPS: Not specified
  • Margins: Gross margin 74.4% (-197 bps YoY), EBITDA margin 17.6% (+154 bps YoY), PAT margin 7.1% (+11 bps YoY)

H1 FY27 Performance:

  • Revenue: ₹7,251 mn (+24.9% YoY)
  • EBITDA: ₹1,141 mn (+43.4% YoY)
  • PAT: ₹416 mn (+7.5% YoY, +38.8% excluding tax credit)
  • Margins: Gross margin 74.3% (-170 bps YoY), EBITDA margin 15.7% (+202 bps YoY), PAT margin 5.7% (-93 bps YoY)

Drivers of financial performance: Higher revenue growth, operational efficiencies, better product mix, and vertical integration of critical components

Comparison to market estimates: Not specified

Key Risks: Raw material price hikes, regulatory risks, supply chain disruptions, currency movements, geopolitical events

Geographical Revenue Split

H1 FY27 Regional Breakdown:

  • Domestic (India): 24% share
  • Export: 76% share (Europe 36%, Rest of World 40%)
  • Regional breakdown: Europe steady growth, Rest of World fastest growth

Balance Sheet Snapshot

As of September 30, 2026:

  • Total Equity: ₹7,453 mn (vs ₹7,023 mn as of Mar 31, 2026)
  • Borrowings: ₹3,017 mn (vs ₹2,695 mn as of Mar 31, 2026)
  • Net Debt: ₹2,235 mn
  • Inventory: ₹3,303 mn (at cost)
  • Trade Receivables: ₹3,181 mn
  • Cash & Cash Equivalents: ₹1,143 mn
  • ROCE: 16.7%
  • ROE: 11.2%

Financial Health Insights: Improved returns ratios, strong revenue growth, manageable leverage with net debt/EBITDA at 0.98x

Capex & Cash Flow Health

H1 FY27:

  • Cash from operations: ₹473 mn
  • Net capex: ₹(415) mn
  • Lease payments: ₹(76) mn
  • Free cash flow after leases: ₹(18) mn

Cash Conversion Trend:

  • FY24: ₹411 mn cash from operations
  • FY25: ₹735 mn cash from operations
  • FY26: ₹1,052 mn cash from operations
  • H1 FY27: Converting 62% of EBITDA to operating cash flow

Investment Rationale: Focus on capacity expansion, technology upgrades, and vertical integration

Strategic & R&D Initiatives

Investments in Innovation:

  • R&D team of 156 members with Masters and PhDs
  • R&D spend at ~9-10% of revenue (FY24 to H1 FY27)
  • Key products: Hydra TAVI platform, Hydra Elevate with external skirt, AVDC 1.5 delivery system, Sironity sirolimus drug-coated balloon
  • 118 patents granted, 79 additional patents in pipeline, 5 design registrations, 75 clinical studies

Expected impact on growth: New product launches expected to contribute to revenue growth and market expansion

Strategic Rationale: Expanding into high-growth markets, reducing operational costs through vertical integration

Industry Trends & Business Environment

Macro/Industry Trends: Stringent regulatory requirements (EU MDR transition period ends Dec 31, 2027), increasing competition, pricing pressure

Impact on Company: Focus on regulatory compliance, clinical evidence generation, and maintaining quality standards

Management Commentary & Growth Outlook

Strategic Outlook: "Our priorities are unchanged: disciplined execution, sustained investment in R&D and clinical evidence, and better quality of cash flows" - Bhargav Dhirajlal Kotadia, MD & CEO

FY Guidance: Not explicitly stated but focused on margin improvement through richer product mix, vertical integration, better plant utilization, and overhead control

Market Share Targets: Not specified

Risks and Opportunities: Economic conditions, competition, regulatory approvals, supply chain risks, technology disruptions

ESG Updates

Not specified

Digital Transformation

Not specified